BR112013022416A2 - derivados de sec-hidróxi-ciclohexila como inibidores de hsl para o tratamento de diabetes - Google Patents

derivados de sec-hidróxi-ciclohexila como inibidores de hsl para o tratamento de diabetes

Info

Publication number
BR112013022416A2
BR112013022416A2 BR112013022416A BR112013022416A BR112013022416A2 BR 112013022416 A2 BR112013022416 A2 BR 112013022416A2 BR 112013022416 A BR112013022416 A BR 112013022416A BR 112013022416 A BR112013022416 A BR 112013022416A BR 112013022416 A2 BR112013022416 A2 BR 112013022416A2
Authority
BR
Brazil
Prior art keywords
diabetes
treatment
sec
hydroxy
hsl
Prior art date
Application number
BR112013022416A
Other languages
English (en)
Portuguese (pt)
Inventor
Daniel Hunziker
Werner Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112013022416A2 publication Critical patent/BR112013022416A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
BR112013022416A 2011-03-16 2012-03-13 derivados de sec-hidróxi-ciclohexila como inibidores de hsl para o tratamento de diabetes BR112013022416A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11158386 2011-03-16
PCT/EP2012/054307 WO2012123432A1 (en) 2011-03-16 2012-03-13 Sec-hydroxycyclohexyl derivatives as hsl inhibitors for the treatment diabetes

Publications (1)

Publication Number Publication Date
BR112013022416A2 true BR112013022416A2 (pt) 2016-12-13

Family

ID=45812793

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013022416A BR112013022416A2 (pt) 2011-03-16 2012-03-13 derivados de sec-hidróxi-ciclohexila como inibidores de hsl para o tratamento de diabetes

Country Status (10)

Country Link
US (1) US8722721B2 (enExample)
EP (1) EP2686299A1 (enExample)
JP (1) JP6117709B2 (enExample)
KR (1) KR20140022840A (enExample)
CN (1) CN103415506B (enExample)
BR (1) BR112013022416A2 (enExample)
CA (1) CA2830126A1 (enExample)
MX (1) MX339513B (enExample)
RU (1) RU2013142647A (enExample)
WO (1) WO2012123432A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097634B2 (en) * 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
US8809384B2 (en) * 2011-03-25 2014-08-19 Hoffmann-La Roche Inc. Azaspirodecanone compounds
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
CN104788360B (zh) * 2015-03-30 2017-07-25 曲阜师范大学 3‑砜基螺环三烯酮类化合物及其制备方法
CN117551046B (zh) * 2023-11-17 2025-10-28 广东药科大学附属第一医院 二氨基脲类hsl抑制剂、制备方法及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10247680B4 (de) * 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase
EP1529528A1 (en) * 2003-11-07 2005-05-11 Universitätsklinikum Freiburg 2-pyrrolidone derivatives and their use in protecting mammalian cells against oxidation stress
US20070208001A1 (en) * 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
US7968585B2 (en) * 2006-04-25 2011-06-28 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US8329904B2 (en) * 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
US8440710B2 (en) * 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
TW201118069A (en) * 2009-10-28 2011-06-01 Lundbeck & Co As H Spirolactam derivatives and uses of same
US8389539B2 (en) * 2009-12-01 2013-03-05 Hoffman-La Roche Inc. Azacyclic derivatives
US8097634B2 (en) * 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
JP2013526530A (ja) 2010-05-11 2013-06-24 サノフイ 置換されたｎ−フェニルスピロラクタムビピロリジン、その製造及び治療上の使用

Also Published As

Publication number Publication date
CA2830126A1 (en) 2012-09-20
CN103415506A (zh) 2013-11-27
JP6117709B2 (ja) 2017-04-19
RU2013142647A (ru) 2015-04-27
EP2686299A1 (en) 2014-01-22
WO2012123432A1 (en) 2012-09-20
US8722721B2 (en) 2014-05-13
MX2013010006A (es) 2013-12-06
CN103415506B (zh) 2015-08-05
HK1190706A1 (en) 2014-07-11
JP2014508178A (ja) 2014-04-03
KR20140022840A (ko) 2014-02-25
MX339513B (es) 2016-05-30
US20120238613A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
BR112014010644A2 (pt) novos derivados de aril-quinolina
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
BRPI1016219B8 (pt) composto indazol substituído com oxazol, e, composição farmacêutica
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112012017269A2 (pt) compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos
BR112012026147A2 (pt) espiroderivados azacíclicos como inibidores de hsl
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112014003693A2 (pt) amino quinazolinas como inibidores de quinase
BR112013018732A2 (pt) novos derivados de amida de aril-benzocicloalquila
CL2012000937A1 (es) Compuestos heterociclicos espiro derivados de ciclohexano, inhibidores de hsl; procedimiento de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de diabetes, sindrome metabolico, dislipidemia, aterosclerosis u obesidad.
BR112014029139A8 (pt) compostos inibidores da atividade de catecol o-metiltransferase
MA33937B1 (fr) Composes pyrazole comme antagonistes du recepteur crth2
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
CR11483A (es) Inhibidores de peptido desformilasa
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
EA201490643A1 (ru) Новые производные бетулиновой кислоты с противовирусной активностью
BR112015024109A2 (pt) derivados de ureia e seu uso como inibidores de proteína de ligação de ácidos graxos (fabp)
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).
DOP2012000260A (es) Uso de nuevos inhibidores de pan–cdk para tratar tumores

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.